This company has been marked as potentially delisted and may not be actively trading. Capstar Special Purpose Acquisition (CPSR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CPSR vs. MOR, GMTX, CALT, ZYME, CMRX, CDMO, SBTX, RVNC, CKPT, and MBXShould you be buying Capstar Special Purpose Acquisition stock or one of its competitors? The main competitors of Capstar Special Purpose Acquisition include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), Silverback Therapeutics (SBTX), Revance Therapeutics (RVNC), Checkpoint Therapeutics (CKPT), and MBX Biosciences (MBX). These companies are all part of the "medical" sector. Capstar Special Purpose Acquisition vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Chimerix Avid Bioservices Silverback Therapeutics Revance Therapeutics Checkpoint Therapeutics MBX Biosciences MorphoSys (NASDAQ:MOR) and Capstar Special Purpose Acquisition (NYSE:CPSR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation. Does the media prefer MOR or CPSR? In the previous week, MorphoSys' average media sentiment score of 0.00 equaled Capstar Special Purpose Acquisition'saverage media sentiment score. Company Overall Sentiment MorphoSys Neutral Capstar Special Purpose Acquisition Neutral Do institutionals & insiders hold more shares of MOR or CPSR? 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 64.9% of Capstar Special Purpose Acquisition shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, MOR or CPSR? MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Capstar Special Purpose Acquisition has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Is MOR or CPSR more profitable? Capstar Special Purpose Acquisition has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Capstar Special Purpose Acquisition's return on equity of 0.00% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Capstar Special Purpose Acquisition N/A N/A N/A Which has preferable earnings and valuation, MOR or CPSR? Capstar Special Purpose Acquisition has lower revenue, but higher earnings than MorphoSys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Capstar Special Purpose AcquisitionN/AN/A-$15.30MN/AN/A SummaryCapstar Special Purpose Acquisition beats MorphoSys on 5 of the 8 factors compared between the two stocks. Get Capstar Special Purpose Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for CPSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPSR vs. The Competition Export to ExcelMetricCapstar Special Purpose AcquisitionPharmaceutical Preparations IndustryMedical SectorNYSE ExchangeMarket Cap$838.53M$782.11M$5.54B$20.53BDividend YieldN/A4.84%5.39%3.77%P/E RatioN/A1.0926.1427.85Price / SalesN/A219.25414.6737.49Price / CashN/A23.4436.1321.91Price / Book-20.605.998.054.55Net Income-$15.30M-$27.64M$3.15B$984.95M Capstar Special Purpose Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPSRCapstar Special Purpose AcquisitionN/A$24.31+0.1%N/A+271.9%$838.53MN/A0.002MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$51.68+0.1%N/A+17.5%$2.24BN/A-51.6830CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks1.958 of 5 stars$12.82+2.8%$21.00+63.8%+44.1%$891.98M$93.38M-8.55460CMRXChimerix0.6731 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.914 of 5 stars$12.50+0.1%$12.25-2.0%+75.5%$799.18M$139.91M-5.23320High Trading VolumeSBTXSilverback TherapeuticsN/A$16.57+4.9%N/A+99.9%$597.48MN/A-6.8583High Trading VolumeRVNCRevance Therapeutics2.7157 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500CKPTCheckpoint Therapeutics0.5593 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210News CoverageMBXMBX Biosciences2.3109 of 5 stars$11.05+13.6%$37.50+239.4%N/A$369.34MN/A0.0036 Related Companies and Tools Related Companies MorphoSys Competitors Gemini Therapeutics Competitors Calliditas Therapeutics AB (publ) Competitors Zymeworks Competitors Chimerix Competitors Avid Bioservices Competitors Silverback Therapeutics Competitors Revance Therapeutics Competitors Checkpoint Therapeutics Competitors MBX Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPSR) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstar Special Purpose Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstar Special Purpose Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
